Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
76 results about "TWEAK RECEPTOR" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Substituted biphenyl-4-carboxylic acid arylamide analogues
Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.
Owner:NEUROGEN
Compounds which modulate the CB2 receptor
Owner:BOEHRINGER INGELHEIM INT GMBH
Pyrrole Derivatives As Pharmaceutical Agents
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
Owner:EXELIXIS INC
Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
Owner:BIOGEN MA INC
Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
Owner:BIOGEN MA INC
Fc receptor modulating compounds and compositions
InactiveUS7332631B2Reduce tissue damageReduced responseUrea derivatives preparationBiocideArylFc(alpha) receptor
The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.
Owner:THE MACFARLANE BURNET INST FOR MEDICAL RES & PUBLIC HEALTH LTD
Methods of treating conditions associated with an Edg-2 receptor
InactiveUS20040192739A1Sufficient effectBiocideCarbohydrate active ingredientsDrug biological activityReceptor for activated C kinase 1
In one aspect, the present invention provides a method for modulating an Edg-2 receptor mediated biological activity in a cell. A cell expressing the Edg-2 receptor is contacted with an modulator of the Edg-2 receptor, which modulates the Edg-2 receptor mediated biological activity. In another aspect, the present invention provides a method for modulating Edg-2 receptor mediated biological activity in a subject. A therapeutically effective amount of an modulator of the Edg-2 receptor is administered to the subject.
Owner:MANIV ENERGY CAPITAL
Compositions and methods for modulation of DARPP-32 phosphorylation
InactiveUS20030171255A1Modulate activityFacilitate ameliorationOrganic active ingredientsBiocideSignalling moleculesMolecular biology
The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-dependent kinase 5 (Cdk5), AMPA receptors, protein phosphatase-1 (PP-1), protein phosphatase 2C (PP2C), protein phosphatase 2B (PP2B) and / or protein phosphatase 2A (PP2A) in cells or tissues. The invention provides methods of treating serotonergic intracellular signaling pathway disorders, e.g., depression. The invention provides methods of treating dopamine-related disorders. The invention provides methods of identifying agents that modulate the activities of serotonergic receptor intracellular signaling molecules, DARPP-32, casein kinase 1, cyclin-dependent kinase 5, AMPA receptors, protein phosphatase-1, protein phosphatase 2C, protein phosphatase 2B and / or protein phosphatase 2A, for use in such treatments. The invention also provides methods of modulating phosphorylation-dependent activation of AMPA receptors for use in such treatments.
Owner:MOBILITY +1
TWEAK receptor
InactiveUS20050208046A1Promote angiogenesisInhibit bindingOrganic active ingredientsFungiAngiogenesis growth factorAgonist
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
Owner:IMMUNEX CORP
Compositions and methods relating to multimeric and oligomeric soluble fragments of the TWEAK receptor
The present invention provides methods and compositions relating to fusion proteins comprising multimeric soluble TWEAK receptor fragments and an oligomerization domain. Such fusion proteins are useful for antagonizing the TWEAK receptor and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and inflammatory conditions.
Owner:AMGEN INC
Anti-OX40 antibodies and methods of using the same
InactiveCN103221427AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntigen bindingIn vivo
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Tweak receptor
The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
Owner:IMMUNEX CORP
Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
Owner:ARENA PHARMA
TWEAK receptor
Owner:IMMUNEX CORP
TWEAK receptor
Owner:IMMUNEX CORP
Neuropeptide q as modulator of GPCR GALR2 and uses thereof
InactiveUS20130196348A1Reduces maximal activationCompound screeningApoptosis detectionNeuropeptide QG protein-coupled receptor
The invention relates to the identification of Neuropeptide Q as ligand of the GALR2 GPCR (G-protein coupled receptor). The invention encompasses the use of the interaction of GALR2 polypeptides and Neuropeptide Q polypeptides as the basis of screening assays for agents that modulate the activity of the GALR2 receptor. The invention also encompasses diagnostic assays based upon the GALR2 / Neuropeptide Q polypeptide interaction, as well as kits for performing diagnostic and screening assays.
Owner:IDORSIA PHARM LTD
Pyrrolidine compounds which modulate the CB2 receptor
Owner:BOEHRINGER INGELHEIM INT GMBH
Compositions and methods for modulation of DARPP-32 phosphorylation
InactiveUS7320785B2Easy to optimizeModulate activityBiocideOrganic active ingredientsSignalling moleculesSignalling pathways
Owner:MOBILITY +1
Methods of identifying agents that selectively activate p38 and/or NFkB signaling
The present invention relates to a method of selectively modulating a signalling pathway of interest controlled by a cell receptor involved in signalling through multiple pathways. The method includes exposing the receptor to an agent that modulates signalling by the receptor through the signalling pathway of interest and does not substantially modulate signalling through one or more other signalling pathways controlled by the receptor.
Owner:FERRANTE ANTONIO +1
4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators
The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined here, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.
Owner:HEPTARES THERAPEUTICS
Alpha (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
InactiveUS20040072993A1Improve immunityEnhance immune responsePeptide/protein ingredientsAntiinfectivesInfectious DisorderAntiendomysial antibodies
The present invention relates to the use of alpha (2) macroglobulin ("alpha2M") receptor as a heat shock protein receptor, cells that express the alpha2M receptor bound to an HSP, and antibodies and other molecules that bind the alpha2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the alpha2M receptor, and modulate the interaction of the alpha2M receptor with its ligand, such as HSPs, and methods for using compositions comprising alpha2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.
Owner:UNIV OF CONNECTICUT HEALTH CENT
Bicyclic GPR119 modulators
The present invention relates to compounds of Formula (I) that are useful for treating, preventing and / or managing the diseases, disorders, syndromes or conditions associated with the modulation of GPR119 receptor activity. The invention also relates to the process for preparation of the compounds, pharmaceutical compositions thereof. The invention further relates to methods of treating, preventing and / or managing diseases, disorders syndromes or conditions associated with the modulation of GPR119 receptor by using either alone or in combinations of Formula (I).
Owner:LUPIN LTD
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.
Owner:ABLYNX NV
Compounds, compositions, and methods for treating diseases
ActiveUS20200339519A1Treating and preventing cancerTreating and preventing painOrganic chemistryPharmaceutical active ingredientsDiseaseCancer prevention
The present application is directed, in part, to compounds, and / or pharmaceutically acceptable salts or solvates thereof, and / or pharmaceutical compositions thereof, for modulating the activity of Sigma I receptor. The present application is further directed, in part, to methods for treating and / or preventing cancer using compounds disclosed herein, and / or pharmaceutically acceptable salts or solvates thereof, and / or pharmaceutical compositions thereof.
Owner:DREXEL UNIV
Receptor-type kinase modulators and methods of use
The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and / or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR.
Owner:SYMPHONY EVOLUTION INC
Neuropeptide Q as modulator of GPCR GALR2 and uses thereof
Owner:IDORSIA PHARM LTD
Methods of Identifying Compounds that Modulate IL-4 Receptor-Mediated IgE Synthesis Utilizing an Adenosine Kinase
InactiveUS20070054862A1Organic active ingredientsPeptide/protein ingredientsIl 4 receptorSurrogate analyte
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
Owner:RIGEL PHARMA
Methods of modulating CD200 receptors
Provided are methods for modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
Owner:SCHERING CORP
Heteroaryl compounds and their use as therapeutic drugs
ActiveUS20170066742A1Effectively inhibiting Mer kinaseAntibacterial agentsOrganic active ingredientsDiseaseEnantiomer
The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament.The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.
Owner:DONG A SOCIO HLDG CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com